Taking stock of the drug industry, from the lab to the medicine chestSeptember 17, 2025Check out STAT+Sponsored By By Ed SilvermanPharmalot Columnist, Senior Writer JORDAN PETTITT/POOL/AFP via Getty Images STAT+ | U.K. debate over investment in pharma grows louder as Trump, an interested party, pays a visit Trump has said European countries need to pay more for drugs. In the U.K. the debate over pharma policy is hitting an inflection point By Andrew Joseph STAT+ | Lilly's GLP-1 pill outperforms Novo's oral treatment in diabetes study In the late-stage trial, Orforglipron helped patients lower blood sugar and weight loss more than Rybelsus. By Elaine Chen STAT+ | Regeneron drug reduces errant bone growth in ultra-rare skeletal condition The drug, garetosmab, which led to a reduction in bone growth in patients with a condition known as FOP, will be submitted to regulators. By Andrew Joseph Adobe Major health insurer group says members will continue to cover vaccines, a step that may ease anxiety over access The announcement by America's Health Insurance Plans, or AHIP, could ease concerns about access if ACIP recommendations change. By Tara Bannow STAT+ | Roivant and Priovant say skin drug brepocitinib succeeded in trial Immune-modifying drug brepocitinib outperformed a placebo in treating a skin condition that impacts 50,000 Americans By Matthew Herper More around STATCheck out more exclusive coverage with a STAT+ subscriptionRead premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.Enjoying Pharmalot? Tell us about your experienceContinue reading the latest health & science news with the STAT appDownload on the App Store or get it on Google Play STAT, 1 Exchange Place, Boston, MA©2025, All Rights Reserved.I no longer wish to receive STAT emailsUpdate Newsletter Preferences • Contact Us • Advertise with Us • View in Browser
No comments